High prevalence of HPV16 and high-grade cytology in women undergoing active surveillance for cervical intraepithelial neoplasia grade 2

被引:5
作者
Damgaard, Rikke Kamp [1 ,2 ,3 ]
Jenkins, David [4 ]
Stoler, Mark H. [5 ]
van de Sandt, Miekel M. [4 ]
Lycke, Kathrine Dyhr [1 ,2 ,3 ]
de Koning, Maurits N. C. [4 ]
Quint, Wim G. V. [4 ,6 ]
Steiniche, Torben [1 ,7 ]
Petersen, Lone Kjeld [8 ,9 ]
Hammer, Anne [1 ,2 ,3 ,10 ]
机构
[1] Aarhus Univ, Dept Clin Med, Aarhus, Denmark
[2] Godstrup Hosp, Dept Obstet & Gynecol, Herning, Denmark
[3] Godstrup Hosp, Ctr Res & Educ, NIDO, Herning, Denmark
[4] Viroclin DDL, Cerba Res Co, DDL Diagnost Lab, Rijswijk, Netherlands
[5] Univ Virginia, Dept Pathol, Charlottesville, VA USA
[6] Methylom, Rijswijk, Netherlands
[7] Aarhus Univ Hosp, Dept Pathol, Aarhus, Denmark
[8] Odense Univ Hosp, Dept Obstet & Gynecol, Odense, Denmark
[9] Univ Southern Denmark, Dept Clin Res, Odense, Denmark
[10] Godstrup Hosp, Dept Obstet & Gynecol, Hospitalsparken 15, DK-7400 Herning, Denmark
关键词
active surveillance; cervical cancer prevention; cervical cancer screening; cervical intraepithelial neoplasia grade 2 (CIN2); cytology; HPV genotype; CANCER; ALGORITHM; RISKS;
D O I
10.1111/aogs.14627
中图分类号
R71 [妇产科学];
学科分类号
100211 ;
摘要
IntroductionMany countries have adopted active surveillance in women with cervical intraepithelial neoplasia grade 2 (CIN2), leaving the lesion untreated. However, there is a lack of consensus on the eligibility criteria for active surveillance across countries, with some abstaining from active surveillance in women with human papilloma virus 16 (HPV16) or a high-grade cytology. Here, we aimed to describe the distribution of HPV genotypes, age, and cytology in women undergoing active surveillance for CIN2. Material and methodsWe conducted a single-center cross-sectional study on women aged 23-40 undergoing active surveillance for CIN2 during 2000-2010. Women were identified through the Danish Pathology Data Bank (DPDB) at Aarhus University Hospital, Denmark. We collected information on basic characteristics and results of histopathological examinations via DPDB. Women were deemed eligible for inclusion if they had a subsequent biopsy after index CIN2, and had no prior record of CIN2+, hysterectomy, or cone biopsy. Archived biopsies underwent HPV genotyping using the HPV SPF10- DEIA-LiPA(25) system, and the diagnosis was re-evaluated by three expert pathologists. We used the Chi squared-test (p-value) for comparison across groups. ResultsWe identified 3623 women with CIN2 of whom 455 (12.6%) were included. Most women were 30 years or younger (73.8%), and half (48.8%) had a high-grade index cytology. The prevalence of any high-risk HPV was 87.0%, with HPV16 being the most prevalent genotype (35.6%). The prevalence of HPV16 was significantly higher in women aged 30 or younger (39.3%) compared to women older than 30 years (25.2%) (p = 0.006). Upon expert review, 261 (57.4%) had CIN2 confirmed, whereas 56 (12.3%) were upgraded to CIN3 and 121 (26.6%) were downgraded to CIN1/normal. While the HPV16 prevalence was similar between community and expert confirmed CIN2, the prevalence of HPV16 was significantly higher in women with expert CIN3 compared to women with expert CIN1/normal (64.3% vs. 19.0%, p = 0.001). ConclusionsThe high prevalence of HPV16 and high-grade cytology imply that these women may be perceived as a high-risk population and non-eligible for active surveillance in countries outside Denmark. Future studies should investigate the importance of HPV, age, cytology, and expert review on risk of progression to help refine criteria for active surveillance.
引用
收藏
页码:1227 / 1235
页数:9
相关论文
共 34 条
[1]  
Anderson L., CLIN QUEST TREATM HI
[2]  
[Anonymous], GYNECOLOGY CANC GUID
[3]  
[Anonymous], CERVICAL CANC PREVEN
[4]   Age-specific HPV type distribution in high-grade cervical disease in screened and unvaccinated women [J].
Aro, Karoliina ;
Nieminen, Pekka ;
Louvanto, Karolina ;
Jakobsson, Maija ;
Virtanen, Seppo ;
Lehtinen, Matti ;
Dillner, Joakim ;
Kalliala, Ilkka .
GYNECOLOGIC ONCOLOGY, 2019, 154 (02) :354-359
[5]   Bayesian analysis of baseline risk of CIN2 and ≥CIN3 by HPV genotype in a European referral cohort [J].
Bonde, Jesper ;
Bottari, Fabio ;
Parvu, Valentin ;
Pedersen, Helle ;
Yanson, Karen ;
Iacobone, Anna D. ;
Kodsi, Salma ;
Landoni, Fabio ;
Vaughan, Laurence ;
Ejegod, Ditte M. ;
Sandri, Maria T. .
INTERNATIONAL JOURNAL OF CANCER, 2019, 145 (04) :1033-1041
[6]   CIN2 is a much less reproducible and less valid diagnosis than CIN3: Results from a histological review of population-based cervical samples [J].
Carreon, Joseph D. ;
Sherman, Mark E. ;
Guillen, Diego ;
Solomon, Diane ;
Herrero, Rolando ;
Jeronimo, Jose ;
Wacholder, Sholom ;
Rodriguez, Ana Cecilia ;
Morales, Jorge ;
Hutchinson, Martha ;
Burk, Robert D. ;
Schiffman, Mark .
INTERNATIONAL JOURNAL OF GYNECOLOGICAL PATHOLOGY, 2007, 26 (04) :441-446
[7]   Performance of carcinogenic human papillomavirus (HPV) testing and HPV16 or HPV18 genotyping for cervical cancer screening of women aged 25 years and older: a subanalysis of the ATHENA study [J].
Castle, Philip E. ;
Stoler, Mark H. ;
Wright, Thomas C., Jr. ;
Sharma, Abha ;
Wright, Teresa L. ;
Behrens, Catherine M. .
LANCET ONCOLOGY, 2011, 12 (09) :880-890
[8]   Performance of HPV E4 and p16INK4a biomarkers in predicting regression of cervical intraepithelial neoplasia grade 2 (CIN2): protocol for a historical cohort study [J].
Damgaard, Rikke Kamp ;
Jenkins, David ;
de Koning, Maurits N. C. ;
Quint, Wim G., V ;
Stoler, Mark H. ;
Doorbar, John ;
Kahlert, Johnny ;
Gravitt, Patti E. ;
Steiniche, Torben ;
Petersen, Lone Kjeld ;
Hammer, Anne .
BMJ OPEN, 2022, 12 (07)
[9]  
Danish National Health Board, 2018, REC SCREEN CERV CANC
[10]  
Danish Society of Obstetrics and Gynecology, 2012, GUID EX TREATM CONTR